S3-E4 – NASH-TAG 2022 Wrap-up: What Did We Learn about Fatty Liver Disease and Clinical Trial Design?
NASH-TAG 2022 Wrap-Up: Finding New Disease Insights and Reconsidering Clinical Trial Design
January 12, 2022
NASH-TAG 2022 Wrap-Up: Finding New Disease Insights and Reconsidering Clinical Trial Design
NASH-TAG 2022 Asks: Are We Ready to Pivot on Testing Methods?
Jeff Lazarus joins the Surfers to discuss the emerging NAFLD Public Health Agenda.
This conversation is part of SurfingNASH’s 2021 NAFLD Year-In-Review. Co-host Dr. Stephen Harrison joins Louise Campbell and Roger Green to review five key NASH themes that emerged in 2021, while simultaneously discussing the year for Surfing the NASH Tsunami.
The last half of December marks our annual NAFLD Year-in-Review. Episodes 62-64 each include ~20 minute segments of longer interviews with Stakeholders who have made a dent in Fatty Liver disease in 2021.
Jörn Schattenberg joins the Surfers to discuss the NASH cost-effectiveness research and related findings on quality of life.
Manal Abdelmalek joins the Surfers to discuss strategies for treating cirrhotic patients today and how NASH drug development and disease knowledge will improve treatment over time.
SurfingNASH’s 2021 NAFLD year-in-review looks at artificial intelligence, non-invasive testing and patient activism.
Drs. Michael Charlton and Mazen Noureddin and Global Liver Institute Director of Global NASH Programs Jeff McIntyre join Dr. Stephen Harrison, Louise Campbell and Roger Green to review some of the most important and exciting presentations from the final two days of the 2021 TLMdX, the annual meeting of AASLD
In the first conversation from SurfingNASH’s AASLD 2021 preview, Manal Abdelmalek, Ken Cusi and Jörn Schattenberg join Louise Campbell and Roger Green to focus on some of the basic NASH Science presentations during the first two days of the meeting.